Apr 17, 2014 04:05PM Amgen Announces Webcast of 2014 First Quarter Financial Results
Apr 4, 2014 09:00AM Amgen Provides Update On Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Mar 30, 2014 08:00AM Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On S
Mar 29, 2014 02:00PM New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Plac
Mar 26, 2014 04:18PM Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology's 63rd Annual Scientific Session
Mar 24, 2014 06:54PM Phase 3 Pivotal Data On Amgen's Novel Investigational Cholesterol-Lowering Medicine To Be Featured At The American College of Cardiology's 63rd Annual Scientific Session
Mar 17, 2014 09:18AM Amgen Announces Positive Top-Line Results From Phase 3 TESLA Trial Of Evolocumab (AMG 145) In Patients With Homozygous Familial Hypercholesterolemia
Mar 14, 2014 05:15PM Amgen's Talimogene Laherparepvec Reduced Size Of Melanoma Tumors In New Phase 3 Retrospective Analysis
Mar 11, 2014 03:30AM Bayer and Onyx Report Phase 3 Study Results of NEXAVAR® (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Mar 5, 2014 04:41PM Amgen Announces 2014 Second Quarter Dividend
Mar 1, 2014 01:26PM Amgen To Present At The Cowen And Company 34th Annual Healthcare Conference
Feb 21, 2014 04:30PM Amgen To Present At The RBC Capital Markets' Global Healthcare Conference
Feb 5, 2014 06:15AM Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma
Jan 30, 2014 04:39PM Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 Trial Of Evolocumab (AMG 145) In Patients With Heterozygous Familial Hypercholesterolemia
Jan 28, 2014 04:03PM Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 Trial Of Evolocumab (AMG 145) In Combination With Statins In Patients With High Cholesterol
Jan 28, 2014 04:02PM Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
Jan 23, 2014 04:07PM Amgen Announces Webcast of 2013 Fourth Quarter and Full Year Financial Results
Jan 23, 2014 09:15AM Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 Trial Of Evolocumab (AMG 145) In Statin Intolerant Patients With High Cholesterol